Skip to content
BioSupply Trends Quarterly logo
  • About Us
  • About Us
Subscribe
  • News
    • Artificial Intelligence
    • Biosimilars
    • Clinical Trials
    • COVID
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Therapeutics
    • Vaccines
    • Washington Report
  • Industry Insight
    • Artificial Intelligence
    • Biosimilars
    • Chronic Illness
    • COVID
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
  • Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • News
    • Artificial Intelligence
    • Biosimilars
    • Clinical Trials
    • COVID
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Therapeutics
    • Vaccines
    • Washington Report
  • Industry Insight
    • Artificial Intelligence
    • Biosimilars
    • Chronic Illness
    • COVID
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
  • Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • Home
  • News
    • All News
    • Artificial Intelligence
    • Biosimilars
    • Clinical Trials
    • COVID
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Therapeutics
    • Vaccines
    • Washington Report
  • Industry Insight
    • All Industry Insight
    • Artificial Intelligence
    • Biosimilars
    • Chronic Illness
    • COVID
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
  • Operations & Management
    • All Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • All Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • Subscribe
  • About Us
  • Home
  • News
    • All News
    • Artificial Intelligence
    • Biosimilars
    • Clinical Trials
    • COVID
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Therapeutics
    • Vaccines
    • Washington Report
  • Industry Insight
    • All Industry Insight
    • Artificial Intelligence
    • Biosimilars
    • Chronic Illness
    • COVID
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
  • Operations & Management
    • All Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • All Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • Subscribe
  • About Us
BioSupply Trends Quarterly logo

Category: Washington Report

Initial Guidance Established for Medicare Drug Price Negotiation Program for Price Applicability Year 2026

Initial Guidance Established for Medicare Drug Price Negotiation Program for Price Applicability Year 2026

For the first time, Medicare will have the ability to negotiate lower prescription drug prices because of the Inflation Reduction Act, a law that lowers healthcare and prescription drug costs.

HHS Creates New Office of Family Violence Prevention and Services

HHS Creates New Office of Family Violence Prevention and Services

The U.S. Department of Health and Human Services has announced a new Office of Family Violence Prevention and Services under the Administration for Children and Families Act.

Grants Provided for Certified Behavioral Health Clinics

Grants Provided for Certified Behavioral Health Clinics

Two funding opportunities for Certified Community Behavioral Health Clinic expansion, totaling $123.6 million, were made available by the U.S. Department of Health and Human Services.

HHS Issues Amendment to PREP Act for Medical Countermeasures Against COVID-19

HHS Issues Amendment to PREP Act for Medical Countermeasures Against COVID-19

The U.S. Department of Health and Human Services (HHS) has issued an amendment to the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19.

NIH Provides $5.3 Million Grant to Study Down Syndrome

NIH Provides $5.3 Million Grant to Study Down Syndrome

The first clinical trial for Down syndrome regression disorder is being funded by a five-year $5.3 million grant.

HHS Issues Bulletin to Highlight Online Tracking Technology Obligations Under HIPAA Rules

HHS Issues Bulletin to Highlight Online Tracking Technology Obligations Under HIPAA Rules

The Office for Civil Rights issued a bulletin to highlight the obligations of the Health Insurance Portability and Accountability Act of 1996 on covered entities and business associates when using online tracking technologies.

$245 Million Awarded by HHS to Support Youth Mental Health

$245 Million Awarded by HHS to Support Youth Mental Health

The U.S. Department of Health and Human Services has awarded nearly $245 million in Bipartisan Safer Communities Act funding to support the integration of mental health training into the training of primary care clinicians.

HHS Invests $13 Million to Grow and Strengthen the Nursing Workforce

HHS Invests $13 Million to Grow and Strengthen the Nursing Workforce

The U.S. Department of Health and Human Services has awarded $13 million to bolster nursing education and training to grow the nursing workforce and improve access to nursing education.

HHS Releases New Reports on Positive Impact of Inflation Reduction Act on Prescription Drug Prices

Inflation Reduction Act

The U.S. Department of Health and Human Services released two new reports that illustrate the urgency of addressing skyrocketing prescription drug costs in the U.S.

Report Released on Chronic Diseases and Related Risk Factors

Doctor reading medical reports

The U.S. Centers for Disease Control and Prevention released the 2021 data from the Behavioral Risk Factor Surveillance System, which are now available through CDC’s easy-to-use web-based tool.

← Previous
Next →
BioSupply Trends Quarterly logo
FFF Enterprises logo
  • Current Issue
  • Past Issues
  • Resources
  • Current Issue
  • Past Issues
  • Resources
  • About BSTQ
  • Subscribe to BSTQ
  • eNewsletter Opt-in
  • Contact Us
  • About BSTQ
  • Subscribe to BSTQ
  • eNewsletter Opt-in
  • Contact Us
  • Advertiser Information
  • Media Kit
  • Editorial Calendar
  • Editorial Guidelines
  • Advertiser Information
  • Media Kit
  • Editorial Calendar
  • Editorial Guidelines
Facebook-f Instagram Linkedin-in Youtube

FFF Enterprises.com | Privacy Statement | Terms of Use | California Consumer Privacy Act (CCPA) Opt-Out Icon

FFF Enterprises.com
Privacy Statement
Terms of Use
California Consumer Privacy Act (CCPA) Opt-Out Icon

©2024 FFF Enterprises, Inc. All Rights Reserved. Property of FFF Enterprises, Inc.

The information provided on this website is not medical advice, nor is it intended to be a substitute for medical advice, diagnosis, and treatment. Always seek the advice of a physician or other qualified health provider with questions concerning a medical condition. Never disregard professional medical advice, or delay seeking it based on information provided on this website.